Experimental flu vaccine enters human testing
NCT ID NCT06863142
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times
Summary
This early-stage trial tests an experimental flu vaccine called FluMos-v2, with or without an adjuvant (ALFQ), in 45 healthy adults aged 18-50. Participants receive two shots four months apart and are followed for 15 months. The goal is to check safety and how well the vaccine triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FluMos-v2 vaccine with or without ALFQ adjuvant
- What this could lead to
- If successful, this could lead to a more effective flu vaccine that protects against multiple strains.
- What could go wrong
- This is an early Phase 1 trial with only 45 people, so safety and immune response are still being tested. The vaccine may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One pill to stop the flu from spreading at home? a new trial puts sebaloxavir to the test.
- Moderna's mRNA vaccine cocktail passes early safety check
- New flu vaccine trial aims for stronger, Longer-Lasting protection
- Universal flu vaccine takes first step in human trial
- New mRNA flu shot shows promise in large trial for older adults